Back |
home / stock / algs / algs message board
Subject | By | Source | When |
---|---|---|---|
ALGS -40%/PM on discontinuation of lead HBV candidate for lack of efficacy: | DewDiligence | investorshub | 01/06/2022 2:13:59 PM |
$ALGS(-16%)sells 5.06M* shares @$19.00a 20% discount to Mondays close: | DewDiligence | investorshub | 07/01/2021 1:58:34 PM |
ALGS(-11%)presents EASL HBV lineup: | DewDiligence | investorshub | 06/15/2021 6:53:47 PM |
News, Short Squeeze, Breakout and More Instantly...
Aligos Therapeutics Inc. Company Name:
ALGS Stock Symbol:
NASDAQ Market:
SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive...
SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced six abstr...
Topline data now projected in early Q4 2024 Rohit Loomba, MD, MHSc to serve as Principal Investigator SOUTH SAN FRANCISCO, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused ...